Skip to main content

Table 1 Physician-reported reasons for choosing the 2nd line drug

From: Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Variable Nilotinib Dasatinib Totaln (%) p-value(2 sided)
Accessibility of the drug in physician institution
 Not at all 34 (94.44) 29 (93.55) 63 (94.03) 1
 Very much 2 (5.56) 2 (6.45) 4 (5.97)  
Cost of drug
 Not at all 33 (91.67) 29 (93.55) 62 (92.54) 0.081
 A little 3 (8.33) 0 (0) 3 (4.48)  
 Quite a bit 0 (0) 2 (6.45) 2 (2.99)  
Patient comorbidity profile
 Not at all 15 (41.67) 13 (41.94) 28 (41.79) 0.977
 A little 6 (16.67) 4 (12.9) 10 (14.93)  
 Quite a bit 13 (36.11) 13 (41.94) 26 (38.81)  
 Very much 2 (5.56) 1 (3.23) 3 (4.48)  
Patient’s age
 Not at all 18 (50) 13 (41.94) 31 (46.27) 0.797
 A little 5 (13.89) 7 (22.58) 12 (17.91)  
 Quite a bit 11 (30.56) 10 (32.26) 21 (31.34)  
 Very much 2 (5.56) 1 (3.23) 3 (4.48)  
Patient’s personality profile
 Not at all 9 (25) 11 (35.48) 20 (29.85) 0.534
 A little 7 (19.44) 8 (25.81) 15 (22.39)  
 Quite a bit 18 (50) 10 (32.26) 28 (41.79)  
 Very much 2 (5.56) 2 (6.45) 4 (5.97)  
Previous discussion about Pros and Cons of both treatments
 Not at all 5 (13.89) 3 (9.68) 8 (11.94) 0.455
 A little 3 (8.33) 7 (22.58) 10 (14.93)  
 Quite a bit 24 (66.67) 18 (58.06) 42 (62.69)  
 Very much 4 (11.11) 3 (9.68) 7 (10.45)  
Different treatment schedules
 Not at all 21 (58.33) 13 (41.94) 34 (50.75) 0.615
 A little 6 (16.67) 7 (22.58) 13 (19.4)  
 Quite a bit 7 (19.44) 8 (25.81) 15 (22.39)  
 Very much 2 (5.56) 3 (9.68) 5 (7.46)  
Type of mutation during IM therapy
 Not at all 31 (86.11) 26 (83.87) 57 (85.07) 0.460
 Quite a bit 4 (11.11) 2 (6.45) 6 (8.96)  
 Very much 1 (2.78) 3 (9.68) 4 (5.97)